Curriculum vitae Europass

Informaţii personale

Nume / Prenume	**IOANA OCTAVIA AGACHE**
Adresă(e)	Nicolae Bălcescu 56, Braşov 500019, Romania
Telefon(oane)	0268 51 66 88 Mobil: 0723 26 50 23
Fax(uri)	0268 51 66 89
E-mail(uri)	ibrumaru@unitbv.ro
Naţionalitate(-tăţi)	Română
Data naşterii	10 Octombrie 1970
Sex	Feminin

Aria tematică de competență și interes

Alergia - mecanisme imunologice, evaluare, tratament

Experienţa profesională

2017-prezent

Profesor universitar

Disciplina Imunologie-Alergologie si Fiziologie

Universitatea Transilvania din Braşov, Facultatea de Medicină, Departamentul de Discipline Fundamentale, Profilactice si Clinice

2008-2017

Conferențiar universitar

Disciplina Imunologie-Alergologie

Universitatea Transilvania din Braşov, Facultatea de Medicină, Departamentul de Discipline Fundamentale, Profilactice si Clinice

2006-2008

Lector universitar

Disciplina Imunologie-Alergologie

Universitatea Transilvania din Braşov, Facultatea de Medicină, Catedra de Medicină Internă

2000-2006

Asistent universitar

Disciplina Imunologie-Alergologie

Universitatea Transilvania din Braşov, Facultatea de Medicină, Catedra de Medicină Internă

1996-2000

Preparator universitar

Disciplina Imunologie-Alergologie

Universitatea Transilvania din Braşov, Facultatea de Medicină, Catedra de Medicină Internă

2006-prezent

Director medical, şef compartiment Alergologie şi Imunologie Clinică

Theramed Healthcare – Centru Național de Alergie și Astm, Braşov

2004-2007

Medic primar alergologie şi imunologie clinică

Spitalul Judeţean Clinic de Urgenţă Braşov, Compartimentul de Alergologie-Imunologie

2000-2004

Medic specialist alergologie şi imunologie clinică

Spitalul Judeţean Clinic de Urgenţă Braşov, Compartimentul de Alergologie-Imunologie

Educaţie şi formare

2005

Doctor în medicină cu distincţia *Magna Cum Laude*

Infecţia cu Chlamydia pneumoniae şi evoluţia la 3 ani a pacienţilor cu sindroame coronariene acute Conducător ştiinţific prof. dr. Alexandru Campeanu

Universitatea de Medicină şi Farmacie "Carol Davila" Bucureşti

1999-2004

Medic primar Alergologie şi Imunologie Clinică

Universitatea de Medicină şi Farmacie "Carol Davila" Bucureşti

1994-1999

Medic specialist Alergologie şi Imunologie Clinică

Universitatea de Medicină şi Farmacie "Carol Davila" Bucureşti

1988-1994

Specializarea medicină generală

Universitatea de Medicină şi Farmacie "Carol Davila" Bucureşti

1984-1988

Colegiul Naţional „Andrei Şaguna" Braşov

Membru al unor societăţi ştiinţifice

2017-2019

Presedinte al Academiei Europeane de Alergologie și Imunologie Clinică (EAACI)

2013-2017

Vice-Presedinte, Academia Europeană de Alergologie și Imunologie Clinică (EAACI)

2009-2013

Membru in Executive Committee, Academia Europeană de Alergologie și Imunologie Clinică (EAACI)

din 2008

Membru in ARIA (Allergic Rhinitis and Impact on Asthma) Advisory Committee

2005-2009

Secretar al Sectiunii de Astm, Academia Europeană de Alergologie și Imunologie Clinică (EAACI)

Din 2005

Membru a Scientific Program Committee, Academia Europeană de Alergologie și Imunologie Clinică (EAACI)

2008-2009

Membru in Asthma Special Committee, Communication Council si Allergy Diagnosis Special Committee, World Allergy Organisation

Membru a Societatii Europeane de Alergologie şi Imunologie Clinică (EAACI) din 1997

Membru a Societatii Europene de Boli Respiratorii (ERS) din 200

Membru a World Allergy Organisation din 2008

Membru a Societatii Americane de Boli Respiratorii (ATS) din 2007

Membru a Junior Members and Affiliates Working Group din cadrul EAACI 2000-2005

Membru a Societatii Române de Alergologie şi Imunologie Clinică din 1995

Membru a Societatii Române de Biologie Moleculară din 2004

Membru în colegiul de redacţie al unor publicaţii ştiinţifice

2010 - prezent

Editor Asociat, Clinical and Translational Allergy

2015 - prezent

Membru în comitetul de redacție, Polish Journal of Allergology

2009-2013

Editor Newsletter, EAACI

2005-2007

Redactor şef adjunct, revista Societăţii Române de Alergologie şi Imunologie Clinică

2007-2008

Membru în colegiu de redacţie, revista Societăţii Române de Alergologie şi Imunologie Clinică

Aptitudini şi competenţe personale

Limba(i) maternă(e) **Româna**

Limba(i) străină(e) cunoscută(e)

Înţelegere				Vorbire				Scriere	
Autoevaluare									
Nivel european (*)	Ascultare		Citire		Participare la conversaţie		Discurs oral		Exprimare scrisă	
Limba Engleza	Avansat		Avansat		Avansat		Avansat		Avansat	
Limba Franceză	Avansat		Avansat		Avansat		Avansat		Avansat	
Limba Italiană	Mediu		Mediu		Mediu		Mediu		Mediu	

(*) Nivelul Cadrului European Comun de Referinţă Pentru Limbi Străine

Competenţe şi abilităţi sociale

Abilități de comunicare
Abilitatea de a lucra în echipă

Competenţe şi aptitudini organizatorice

- Organizator local simpozion PAPRICA în colaborare cu EAACI – Brașov, 8 Octombrie 2011
- Membru în comitetul ştiinţific al XXVII EAACI Congress: Clinical Features of Allergy: From Pediatric to Geriatric, Barcelona, 7-11 iunie 2008
- Membru în comitetul ştiinţific al XXVI EAACI Congress, Goteborg, 9-13 iunie 2007
- Membru în comitetul ştiinţific al XXV EAACI Congress, Viena, 10-14 iunie 2006
- Membru în comitetul ştiinţific Interasthma – EAACI Joint Meeting, Bilbao, 28 noiembrie 2004
- Membru în comitetul internaţional de organizare a Congresului Internaţional de Astmologie (World Congress of Asthma), Monte Carlo, 5-8 Noiembrie 2008
- Membru în comitetul internaţional de organizare a școlii de vară cu tema “Paediatric asthma” organizată de Academia Europeană de Alergologie și Imunologie Clinică la Veneția, 4-6 iulie 2008
- Membru în comitetul internaţional de organizare a școlii de vară “Asthma and allergy: bridging the gap between basic and clinial science ” organizată de Academia Europeană de Alergologie și Imunologie Clinică la Rotterdam, 28-31 august 2005
- Membru în comitetul de organizare al 4th Balkan Congress of Allergology & Clinical Immunology, Bucureşti, 22-25 Septembrie 2005

- Membru în comitetul ştiinţific al Conferinţei Anuale de Alergologie şi Imunologie Clinică, Bucuresti, Octombrie 2009
- Membru în comitetul ştiinţific al Conferinţei Anuale de Alergologie şi Imunologie Clinică, Baia Mare,1-4 Mai 2008
- Membru în comitetul ştiinţific al Congresului Societăţii Române de Alergologie şi Imunologie Clinică cu participare internaţională, Târgu Mureş, 26-28 Aprilie 2007

- Membru în comitetul ştiinţific al conferinţei, în comitetul de organizare şi chairperson al Conferinţei Naţionale Anuale a Societăţii Române de Alergologie şi Imunologie Clinică cu participare internaţională, Braşov, 07-09 Octombrie 2004
- 2002-2008, Adjunct şef catedră Medicină Internă, Facultatea de Medicină, Universitatea Transilvania din Braşov
- 2004-2008, Membru în Consiliu Profesional al Facultăţii de Medicină, Universitatea Transilvania din Braşov
- 2004-2006, Membru în Comitetul Director al Societăţii Române de Alergologie şi Imunologie Clinică
- 2005-2006, Membru în Comisia de Alergologie din cadrul comisiilor de specialiate a Ministerul Sănătăţii Publice

Competenţe şi aptitudini tehnice

Viasys Continuing Education: Certificate of Attendace for MasterScope CT, 2008

Competenţe şi aptitudini de utilizare a calculatorului

Aptitudini şi competenţe tehnice: utilizare calculator, navigare internet

Alte competenţe şi aptitudini

- Chairperson la XXVII EAACI Congress, Barcelona, 7-11 iunie 2008: Symposium - Relationship Between Objective and Subjective Outcome Measures in Airway Disease, Symposium - Pro & Con: Mild Persistent Asthma Does Require Regular Treatment, Poster session - Risk Factors and Triggers of Asthma
- Chairperson la EAACI & GA2LEN Allergy Summer School on Pediatric Asthma 2008, Veneția 5-8 iulie 2008: Phenotypes of childhood asthma
- Chairperson la, ERS Congress, Berlin 4-8 octombrie 2008: Understanding allergic airway inflammation with the help of animal models
- Chairperson la World Allergy Congress, Bangkok 2-7 Decembrie 2007: Sister Society Symposium - Interasma Congress 08 Montecarlo - Difficult to Control Asthma
- Chairperson la XXVI EAACI Congress, Goteborg, 9-13 iunie 2007: Symposium - Severe and Difficult to Treat Asthma, Poster session – Asthma and Allergy, Poster session – From Immnodeficiency to Autoimmunity
- Chairperson la XXV EAACI Congress, Viena, 10-14 iunie 2006: Poster session – Clinical and Occupational Asthma
- Chairperson la GA2LEN/EAACI Summer School Rotterdam 2005: How should we assess and monitor asthma?
- Chairperson la Interasthma – EAACI Joint Meeting, Bilbao, 28 noiembrie 2004: Plenary Session Asthma in the world
- Chairperson la XXIII EAACI Congress, Amsterdam 12-16 iunie 2004: JMA Poster Session
- Chairperson la EAACI- Section ENT Meeting, Gent, Belgium, 15-18 November 2003: Plenary Session - Future treatments of nasal disease

Permis(e) de conducere

Categoria B

Informaţii suplimentare

Programe de cercetare naţională si internațională

- 2015-2017, Endotipurile astmului non-eozinofilic la adult, PN-II-RU-TE-2014-4-2303, Director de proiect
- 2014-2017, COST Action BM 1201, Developmental origins of chronic lung disease, STSM Coordinator and member in the WG Infant Lung Development
- 2015-2020, Integrated care pathways for airway diseases (AIRWAYS-ICPs), Working Package 10 of the European Innovation Partnership on Active and Healthy Ageing, Action Plan B3; Mechanisms of the Development of Allergy
- 2008, Propunere de proiect PN-II-ID-PCE-2008-2, „Controlul poluării de interior şi efectele asupra calităţii vieţii copilului", Director de proiect
- 2007, Programul IMPACT, Proiect CERICARD 908/13 iunie 2007 - Laborator de cercetere şi management integrat în insuficienţa cardiacă - admis pentru finanţare - 10472375 lei, Coordonator proiect Prof. Dr. Mariana Rădoi; Funcţie în proiect - Responsabil echipamente şi programe de cercetare fundamentală în insuficienţa cardiacă
- 2007 - 2010, Contract de cercetare PN2-ID-146/2007 - Modele de testarea condiţiilor de admisibilitate a proceselor şi produselor din industria lemnului pe pieţele europene, cu impact direct asupra calităţii mediului, în contextul dezvoltării durabile; valoare 784 705 lei. Coordonator proiect Prof. Dr. Loredana Anne-Marie Bădescu, Membru în echipa de cercetare
- 2004-2007, Proiect CNCSIS contract nr. 1339/2004, Reţea de excelenţă ştiinţifică pentru Industria Lemnului din România în contextul integrării ţării noastre în Uniunea Europeana în 2007, valoare 136.000 lei, Conducător de proiect Prof. Dr. Ing. Loredana Anne-Marie Badescu, Membru în echipa de cercetare
- 2000-2003, Proiect CNCSIS contract 3993/14.06.2000 "Infecţia cu *Chlamydia Pneumoniae* ca factor de risc în sindroame coronariene acute, stroke şi ocluzia arterelor periferice", valoare 100 000 lei, Coordonator proiect Prof. Dr. Mariana Radoi, Membru în echipa de cercetare

Sinteză a principalelor realizări:

- Doctor in medicina in 2005; Titlul tezei "Evoluţia la 3 ani a pacienţilor cu sindroame coronariene acute şi infecţie cu *Chlamydia pneumoniae*"
- nr cărţi publicate în edituri internaționale: 8
- nr capitole de cărți publicate în edituri internaționale: 19
- nr cărţi publicate în edituri naționale 4
- nr capitole de cărți publicate în edituri naționale 3
- nr lucrări indexate ISI 115

Studii de cercetare clinică:

- 2016, Investigator Principal - A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma, sponsor Glaxosmithkline
- 2016, Investigator Principal - A Phase IIb, 24 week, randomized, double-blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once-daily via a dry powder inhaler, versus placebo, in participants with asthma, sponsor Glaxosmithkline
- 2016, Investigator Principal - A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma, sponsor Novartis
- 2016, Investigator Principal - Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment, sponsor Novartis
- 2015, Investigator Principal - Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils, Sponsor Teva Branded Pharmaceutical Products, R&D Inc.
- 2015, Investigator Principal - A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection (SPIRITUS), Sponsor Biota Pharmaceuticals, Inc.
- 2014, Investigator Principal - A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma, sponsor AstraZeneca
- 2014, Investigator Principal - An Open-label, Multi-center, Extension Study to Evaluate the Long-term Safety of Subcutaneous 240mg QGE031 Given Every 4 Weeks for 52 Weeks in Allergic Asthma Patients Who Completed Study CQGE031B2201, sponsor Novartis

- 2014, Investigator Principal - A Randomized, Double-blind, Double-dummy, Parallel Group, Multicenter Study of Once Daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, Twice Daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Twice Daily Fluticasone Propionate 250 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Already Adequately Controlled on Twice-daily Inhaled Corticosteroid and Long-acting beta2 Agonist, Sponsor GlaxoSmithKline
- 2014, Investigator Principal – A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma, Sponsor - AstraZeneca
- 2014, Investigator Principal – A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists, Sponsor Novartis Pharmaceuticals
- 2013, Investigator Principal – A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA), Sponsor - AstraZeneca
- 2013, Investigator Principal – A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study With an Optional Safety Extension Treatment Period up to 6 Months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in Patients With Uncontrolled Persistent Asthma), Sponsor - AstraZeneca
- 2013, Investigator Principal – A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients, Sponsor - AstraZeneca
- 2013, Investigator Principal – A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202), Sponsor - Merck Sharp & Dohme Corp.
- 2012, Investigator Principal – A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Severe Persistent Asthma Uncontrolled on High Dose Inhaled Corticosteroid Therapy, Sponsor Teva Pharmaceutical Industries
- 2012, Investigator Principal – A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Roflumilast 500 µg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS), Sponsor Forest Laboratories
- 2012, Investigator Principal – A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta2-agonist, Sponsor GSK
- 2012, Investigator Principal – A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma, Sponsor Boehringer Ingelheim
- 2012, Investigator Principal - A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet (MT-06), Sponsor ALK-Abelló A/S
- 2012, Investigator Principal – A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA), Sponsor - Genentech

- 2014, Investigator Principal - An Open-label, Multi-center, Extension Study to Evaluate the Long-term Safety of Subcutaneous 240mg QGE031 Given Every 4 Weeks for 52 Weeks in Allergic Asthma Patients Who Completed Study CQGE031B2201, sponsor Novartis
- 2012, Investigator Principal – A 12-week, multinational, multicentre, randomised, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of chf 1535 200/6µg (fixed combination beclomethasone dipropionate / formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled corticosteroids or on medium dose of inhaled corticosteroids plus long-acting β2-agonists, Sponsor - Chiesi Farmaceutici S.p.A
- 2012, Investigator, A 52 week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease, Sponsor GSK
- 2012, Investigator Principal – A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents, Sponsor GSK
- 2011, Investigator - A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD), Sponsor -GSK
- 2011, Investigator - A 48-week, double blind, randomized, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of “fixed combination” beclomethasone dipropionate plus formoterol fumarate administered via pmdi (chf 1535 foster®) versus formoterol in patients with severe chronic obstructive pulmonary disease, Sponsor - Chiesi Farmaceutici S.p.A
- 2010, Investigator Principal – A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 weeks in patients with moderate persistent asthma, Sponsor - Boehringer Ingelheim RCV GmbH & Co KG
- 2009, Investigator Principal – Double-blind, placebo-controlled dose-finding study with CYT003-QbG10 in adult patients with rhinoconjunctivitis due to house dust mite allergy, Sponsor: Cytos Biotechnology
- 2008, Investigator Principal - A 12-week, multinational, randomised, double blind, double dummy, 4-arm parallel-group study comparing the efficacy and safety of CHF 1535 (fixed combination of beclomethasone dipropionate + formoterol fumarate) 100 + 6 µg/actuation inhalation powder, administered via the NEXT inhaler, versus CHF 1535 (fixed combination of beclomethasone dipropionate + formoterol fumarate) 100 + 6 µg/actuation, via HFA pressurised inhalation solution, in moderate to severe symptomatic asthmatic patients aged ≥ 12 years under treatment with inhaled corticosteroids, Sponsor: Chiesi Farmaceutici S.p.A
- 2008, Investigator Principal - Efficacy and safety study of the antihistamine V0114CP 2.5mg in the treatment of Perennial allergic rhinites. Randomised, double-blind, three arm parallel group study including placebo and active control arm (levocetirizine 5mg), Sponsor: Institut de Recherche Pierre Fabre
- 2008, Investigator Principal - A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10µg twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Fluticasone (250µg twice daily) Alone in Skyepharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients with Moderate to Severe Asthma, Sponsor: Kos Life Sciences LLC
- 2008, co investigator - A randomised, 4-week, placebo-controlled, double-blind, 6 arm parallel group, dose-finding clinical trial, to assess the efficacy, safety and pharmacokinetics of three different doses of formoterol (6, 12 & 18µg) combined with the inhaled anticholinergic aclidinium bromide 200µg, aclidinium bromide 200µg monotherapy and formoterol 12µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe Chronic Obstructive Pulmonary Disease, Sponsor: Laboratorios ALMIRALL, S.A.
- 2003, Co-Investigator – Protocol SCO 100470: A multicentre, randomised, double-blind, parallel group, 24-week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD).

- 2007, Investigator Principal – Protocol SKY2028-3-004: A randomized, double-blind, placebo-controlled, parallel group, stratified, multi-center, 12-week study comparing the safety and efficacy of fluticasone and formoterol combination (FlutiForm 100/10 µg or 250-10 µg twice daily) in a single inhaler (SkyePharma hfa pmdi) with the administration of placebo or fluticasone (250 µg twice daily) and formoterol (10 µg twice daily) alone in adolescent and adult patients with moderate to severe asthma, Sponsor: SkyePharma AG.
- 2007, Investigator Principal – A randomised double-blind placebo-controlled study to assess the safety of oral microencapsulated ragweed pollen extract adminnistered for one-year, Sponsor: Curalogic A/S
- 2007, Investigator Principal – A study of the efficacy, safety, and quality of life (QoL) in patients with chronic idiopathic urticaria dosed with AERIUS tablets (5 mg, 10 mg, or 20 mg once daily), Sponsor: Schering-Plough
- 2007, Investigator Principal – Open-label, blinded endpoint, randomized, parallel treatment study to compare the clinical efficacy of PURETHAL Bee and Alutard SQ Bee, Sponsor Hal Allergy BV
- 2006, Investigator Principal – Protocol MK0476-332: A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients With Chronic Asthma Who Smoke Cigarettes, Sponsor: Merck
- 2006, Coinvestigator – A phase III, randomized, parallel study to compare the therapeutic efficacy of SMB BUDESONIDE-SALMETEROL DPI capsule 300/25 µg BID delivered by the Axahaler versus SERETIDE DISKUS 500/50 µg (Fluticasone propionate 500 µg/Salmeterol 50 µg) BID over 12 weeks and evaluate the safety of SMB BUDESONIDE-SALMETEROL 300/25 µg over an additional period of 12 weeks, Sponsor: Remedium Oy
- 2005, Investigator Principal – Protocol RA/PR/033009/004/04: Evaluation of the 24-hour through FEV1 following 7 days of dosing with CHF 4226 2m once daily. A multicenter, double-blind, double-dummy, randomized, parallel group, placebo and active (Formoterol 12 mg bid) controlled study followed by a 3-week open label extension (to either CHF 4226 2mg od or Formoterol 12 mg bid in a 2:1 ratio) for the evaluation of safety and tolerability, Sponsor: Chiesi SA
- 2005, Investigator Principal – Protocol D5899C00001: A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 µg Bid and 2 x 80/4.5 µg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 µg Bid and Placebo in Patients With COPD, Sponsor: AstraZeneca
- 2004, Investigator Principal – Protocol IC05RUP/4/03: A 12-week, multicenter, double-blind, randomised, placebo and active treatment controlled, parallel-group trial to assess the efficacy and safery of rupatadine in the treatment of Seasonal Allergic rhino-conjuncctivitis (SAR), Sponsor: J Uriach y Cia SA
- 2004, Investigator Principal – Protocol IC06RUP/3/04: A 12-week, multicenter, double-blind, randomised, placebo and Cetirizine 10 mg controlled study to assess the efficacy and safery of rupatadine 10 mg in the treatment of perennial allergic rhinitis (PAR), Sponsor: J Uriach y Cia SA
- 2004, Investigator Principal – Protocol BILA 1704/RAE: Double-Blind, Randomised, Placebo-Controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis, Sponsor: Faes Pharma SA
- 2003, Co-investigator – Protocol D3562C00098: Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure, Sponsor: AstraZeneca
- 2003, Investigator Principal – Protocol: SD-039-0734, Efficacy of Symbicort® Turbuhaler® 160/4.5 mcg as needed versus Oxis® 4.5 mcg as needed and Bricanyl® 0.4 mg as needed in adults and adolescents with asthma receiving Symbicort® Turbuhaler® 160/4.5 mcg twice daily as maintenance treatment. A 12-month, randomised, double-blind, parallel-group, active-controlled, phase IIIB, multi-centre study, Sponsor: AstraZeneca
- 2003, Investigator principal – Protocol: SD-NEE-0003 A randomized, double-blind, parallel-group multicentre efficacy and safety phase IIB pilot study of esomeprazole 40 mg twice daily versus placebo twice daily in adult asthmatics treated for 4 months, Sponsor: AstraZeneca

- 2003, Investigator – Protocol SAS30040: A 12-week, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination 50/100mcg bd with fluticasone propionate 250mcg bd, all via the DISKUS™/ACCUHALER™ on maintaining asthma control in moderate persistent asthmatic subjects whose symptoms have been well-controlled following an initial maintenance therapy with salmeterol/fluticasone propionate 50/250mcg combination twice-daily for 12 weeks, Sponsor: GlaxoSmithKline
- 2000, Co-investigator – Protocol SCO30003: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Investigate the Effects of Salmeterol/Fluticasone 50/500mcg Bd, Salmeterol 50mcg Bd, and Fluticasone 500mcg Bd, All Delivered Via the DISKUS/ACCUHALER Inhaler, on the Survival of Subjects With Chronic Obstructive Pulmonary Disease Over 3 Years of Treatment, Sponsor: GlaxoSmithKline

LUCRĂRI RELEVANTE

1. **Agache I**, Rogozea L, *Endotypes in allergic diseases*. Curr Opin Allergy Clin Immunol. 2018;18(3):177-183,
https://insights.ovid.com/pubmed?pmid=29561354

2. **Agache I**. *EAACI guidelines on allergen immunotherapy-Out with the old and in with the new*. Allergy. 2018;73(4):737-738.
https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13393

3. **Agache I**, Strasser DS, Pierlot GM, Farine H, Izuhara K, Akdis CA. *Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma*. J Allergy Clin Immunol. 2018;141(1):442-445
https://www.jacionline.org/article/S0091-6749(17)31569-5/fulltext

4. **Agache I**, Rogozea L. *Asthma Biomarkers: Do They Bring Precision Medicine Closer to the Clinic?* Allergy Asthma Immunol Res. 2017;9(6):466-476.
https://e-aair.org/DOIx.php?id=10.4168/aair.2017.9.6.466

5. Brożek JL, Bousquet J, **Agache I**, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Cuello-Garcia CA, Demoly P, Dykewicz M, Etxeandia-Ikobaltzeta I, Florez ID, Fokkens W, Fonseca J, Hellings PW, Klimek L, Kowalski S, Kuna P, Laisaar KT, Larenas-Linnemann DE, Lødrup Carlsen KC, Manning PJ, Meltzer E, Mullol J, Muraro A, O'Hehir R, Ohta K, Panzner P, Papadopoulos N, Park HS, Passalacqua G, Pawankar R, Price D, Riva JJ, Roldán Y, Ryan D, Sadeghirad B, Samolinski B, Schmid-Grendelmeier P, Sheikh A, Togias A, Valero A, Valiulis A, Valovirta E, Ventresca M, Wallace D, Waserman S, Wickman M, Wiercioch W, Yepes-Nuñez JJ, Zhang L, Zhang Y, Zidarn M, Zuberbier T, Schünemann HJ. *Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision J Allergy Clin Immunol*. 2017;140(4):950-958. FI:13.081
https://www.jacionline.org/article/S0091-6749(17)30919-3/fulltext

6. **Agache I**, Strasser DS, Klenk A, Agache C, Farine H, Ciobanu C, Groenen PM, Akdis CA. *Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics*. Allergy. 2016;71(8):1192-202
http://onlinelibrary.wiley.com/wol1/doi/10.1111/all.12906/full

7. **Agache I**, Akdis CA. *Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine*. Allergol Int. 2016; 65(3):243-52
http://www.sciencedirect.com/science/article/pii/S132389301630048X

8. Muraro A, Lemanske RF, Hellings PW, Akdis CA, Bieber T, Casale TB, Jutel M, Ong PY, Poulsen LK, Schmid-Grendelmeier P, Simon HU, Seys SF, **Agache I**. *Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology*. J Allergy Clin Immunol. 2016;137(5):1347-58
http://www.jacionline.org/article/S0091-6749(16)00456-5/fulltext

9. Jutel M, **Agache I**, Bonini S, Burks AW, Calderon M, Canonica W, Cox L, Demoly P, Frew AJ, O'Hehir R, Kleine-Tebbe J, Muraro A, Lack G, Larenas D, Levin M, Nelson H, Pawankar R, Pfaar O, van Ree R, Sampson H, Santos AF, Du Toit G, Werfel T, Gerth van Wijk R, Zhang L, Akdis CA. *International consensus on allergy immunotherapy*. Journal of Allergy and Clinical Immunology 2015; 136 (3), 556-568
http://www.jacionline.org/article/S0091-6749(15)00775-7/fulltext

10. **Agache I**, Bilò M, Braunstahl GJ, Delgado L, Demoly P, Eigenmann P, Gevaert P, Gomes E, Hellings P, Horak F, Muraro A, Werfel T, Jutel M. *In vivo diagnosis of allergic diseases-allergen provocation tests*. Allergy. 2015;70(4):355-65
http://onlinelibrary.wiley.com/doi/10.1111/all.12586/full

11. **Agache I**, Sugita K, Morita H, Akdis M, Akdis CA. *The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside*. Curr Allergy Asthma Rep. 2015;15(6):29
http://link.springer.com/article/10.1007/s11882-015-0529-x

12. Muraro A, **Agache I**, Clark A, Sheikh A, Roberts G, Akdis CA, et al; *European Academy of Allergy and Clinical Immunology (EAACI) food allergy and anaphylaxis guidelines: managing patients with food allergy in the community*. Allergy. 2014;69(8):1046-57
http://onlinelibrary.wiley.com/doi/10.1111/all.12441/full

13. **Agache I**, Ryan D, Rodriguez MR, Yusuf O, Angier E, Jutel M. *Allergy management in primary care across European countries - actual status*. Allergy. 2013; 68(7): 836-43
http://onlinelibrary.wiley.com/doi/10.1111/all.12150/pdf

14. **Agache I**, Akdis C, Jutel M, Virchow JC. *Untangling asthma phenotypes and endotypes*. Allergy. 2012;67(7):835-46
http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2012.02832.x/pdf

15. Papadopoulos NG, Christodoulou I, Rohde G, **Agache I**, Almqvist C, Bruno A, et al. Viruses and bacteria in acute asthma exacerbations-a GA²LEN-DARE systematic review. Allergy 2011;66(4):458-68. FI: 6,271
http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2010.02505.x/full

16. **Agache I**, Ciobanu C, Agache C, Anghel M. *Increased serum IL-17 is an independent risk factor for severe asthma*. Respir Med. 2010;104(8):1131-7
http://www.resmedjournal.com/article/S0954-6111(10)00088-0/abstract